Mytesi (crofelemer): Diarrhea Relief for HIV/AIDS Therapy

What is Mytesi, and how does it work?

Mytesi (crofelemer delayed-release tablets) is an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

What are the side effects of Mytesi?

Common side effects of Mytesi include:

upper respiratory tract infection,
bronchitis,
cough,
gas,
increased bilirubin,
nausea,
back pain,
joint pain,
urinary tract infection (UTI),
runny or stuffy nose,
musculoskeletal pain,
hemorrhoids,
giardiasis,
anxiety,
increased alanine aminotransferase, and
abdominal bloating.

What is the dosage for Mytesi?

Before starting Mytesi, rule out infectious etiologies of diarrhea.
The recommended adult dosage of Mytesi is 125 mg taken orally two times a day, with or without food.
Do not crush or chew Mytesi tablets.
Swallow whole.

What drugs interact with Mytesi?

Nelfinavir, Zidovudine, And Lamivudine

Mytesi administration did not have a clinically relevant interaction with nelfinavir, zidovudine, or lamivudine in a drug-drug interaction trial.

Is Mytesi safe to use while pregnant or breastfeeding?

There are no adequate, well-controlled studies in pregnant women.
This drug should be used during pregnancy only if clearly needed.
It is not known whether crofelemer is excreted in human milk.
Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from
Mytesi, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.